Novavax’s COVID-19 vaccine 49 percent effective against B.1.351 variant
New data shows NVX-CoV2373 offered complete protection against severe COVID-19 and 60 percent efficacy against infection with the B.1.351 variant in healthy adults.
List view / Grid view
New data shows NVX-CoV2373 offered complete protection against severe COVID-19 and 60 percent efficacy against infection with the B.1.351 variant in healthy adults.
New trial data shows Novavax’s COVID-19 vaccine, NVX–CoV2373, is effective against both the B.1.1.7 UK and the B1.351 South African variants.
A Phase I trial conducted by Novavax to test NVX‑CoV2373, the company’s recombinant COVID-19 vaccine candidate, showed it elicited robust antibody responses.